AMD Standard of Care is Not Enough
According to the American Academy of Ophthalmology IRIS® Registry, eyes that presented with at least 20/40 VA at baseline maintained a mean VA of at least 20/40 after 1 and 2 years of anti-VEGF therapy.1 However eyes that had less than 20/40 VA at baseline, a mean 20/40 VA was not achieved at either 1 or 2 years.
Approximately 66% of patients in the registry presented with VA worse than 20/40, illustrating that a majority of real-world patients lose significant vision before nAMD is detected. Fellow eyes didn’t fare much better at 64%.
1. Ho AC, Kleinman DM, Lum FC, et al. Baseline visual acuity at wet AMD diagnosis predicts long-term vision outcomes: an analysis of the IRIS registry. Ophthalmic Surg Lasers Imaging Retina. 2020;51(11):633-639.
